The SQUIRE trial found that necitumumab combined with chemotherapy prolonged median overall survival (mOS) by 1.6 months (HR=0.84) in patients with metastatic squamous lung cancer, however the cost-benefit relationship for this regimen has not been clarified, and a billing approach based on the degree of benefit is a novel pricing model. Daniel A, an American academic, conducted a study aimed at exploring the range of costs for which chemotherapy combined with necitumumab regimens are cost-effective. (JAMA Oncol. online August 27, 2015) The study divided patients with metastatic squamous lung cancer into 2 groups receiving either (gemcitabine + cisplatin)*6 cycles or (necitumumab + gemcitabine + cisplatin)*6 cycles + necitumumab maintenance regimens in first line, and used Markov models to analyze multi-source data (including SQUIRE trial data) to compare the cost of treatment and life expectancy of patients in the 2 groups. For the SQUIRE trial, survival assessment data and frequency of adverse events were entered into the model, and log-logistic models were used to compare survival differences. Cost inputs included drug costs based on average Medicare sales price, dosing regimen based on Medicare benefit rates, and adverse reaction treatment spend (all in 2014 dollar values). Based on a range of cost and benefit data, the study estimated incremental cost-effectiveness ratios (ICERs) for necitumumab. Based on 10 000 Monte Carlo simulations, probabilistic sensitivity analysis was used to characterize the stability of the model, with sampling values taken from all model parameters. The results showed a survival benefit of 0.15 life years and 0.11 quality-corrected life years (QALYs) for the necitumumab combination regimen. Probability-sensitive analysis suggested that when necitumumab costs less than$563 and$1309 per cycle, there is 90% confidence that the incremental cost-effectiveness ratios (ICERs) for necitumumab will not exceed$100?000/QALY and$200?000/QALY. Therefore, the study proposes that necitumumab benefit-based cost pricing of$563-$1309/per cycle, which provides a benefit-based pricing model for oncology drugs entering the U.S. market.